3SBio（TRSB.F）株式概要投資持株会社である3SBio Inc.は、中国本土および国際的なバイオ医薬品の開発、生産、販売を行っている。 詳細TRSB.F ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績6/6財務の健全性6/6配当金2/6報酬当社が推定した公正価値より58.8%で取引されている 過去1年間で収益は305.8%増加しました リスク分析今後3年間の収益は年平均40.1%減少すると予測されている。 株式の流動性は非常に低い すべてのリスクチェックを見るTRSB.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$2.85375.0% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture018b2016201920222025202620282031Revenue CN¥8.1bEarnings CN¥3.9bAdvancedSet Fair ValueView all narratives3SBio Inc. 競合他社Halozyme TherapeuticsSymbol: NasdaqGS:HALOMarket cap: US$8.0bCatalyst PharmaceuticalsSymbol: NasdaqCM:CPRXMarket cap: US$3.8bAlkermesSymbol: NasdaqGS:ALKSMarket cap: US$6.2bACADIA PharmaceuticalsSymbol: NasdaqGS:ACADMarket cap: US$3.7b価格と性能株価の高値、安値、推移の概要3SBio過去の株価現在の株価HK$2.8552週高値HK$4.7452週安値HK$2.22ベータ0.561ヶ月の変化-5.00%3ヶ月変化-4.52%1年変化n/a3年間の変化n/a5年間の変化187.88%IPOからの変化17.77%最新ニュースお知らせ • Apr 023SBio Inc. Resolves to Declare Final Dividend for the Year Ended 31 December 2025, Payable on or Around 4 August 2026The Board of 3SBio Inc. resolved to declare a final dividend of 25 HK cents per share for the year ended 31 December 2025 (2024: 25 HK cents) to those shareholders whose names appeared on the register of members of the Company on 27 July 2026, which will be paid out of the Company's share premium account. Subject to the approval of shareholders of the Company at the forthcoming annual general meeting ("AGM"), the final dividend will be paid in cash on or around 4 August 2026.お知らせ • Mar 313SBio Inc., Annual General Meeting, Jun 25, 20263SBio Inc., Annual General Meeting, Jun 25, 2026.お知らせ • Mar 173SBio Inc. to Report Fiscal Year 2025 Results on Mar 30, 20263SBio Inc. announced that they will report fiscal year 2025 results on Mar 30, 2026お知らせ • Dec 103SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listingお知らせ • Dec 033SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listingお知らせ • Aug 193SBio Inc. to Report First Half, 2025 Results on Aug 29, 20253SBio Inc. announced that they will report first half, 2025 results on Aug 29, 2025最新情報をもっと見るRecent updatesお知らせ • Apr 023SBio Inc. Resolves to Declare Final Dividend for the Year Ended 31 December 2025, Payable on or Around 4 August 2026The Board of 3SBio Inc. resolved to declare a final dividend of 25 HK cents per share for the year ended 31 December 2025 (2024: 25 HK cents) to those shareholders whose names appeared on the register of members of the Company on 27 July 2026, which will be paid out of the Company's share premium account. Subject to the approval of shareholders of the Company at the forthcoming annual general meeting ("AGM"), the final dividend will be paid in cash on or around 4 August 2026.お知らせ • Mar 313SBio Inc., Annual General Meeting, Jun 25, 20263SBio Inc., Annual General Meeting, Jun 25, 2026.お知らせ • Mar 173SBio Inc. to Report Fiscal Year 2025 Results on Mar 30, 20263SBio Inc. announced that they will report fiscal year 2025 results on Mar 30, 2026お知らせ • Dec 103SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listingお知らせ • Dec 033SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listingお知らせ • Aug 193SBio Inc. to Report First Half, 2025 Results on Aug 29, 20253SBio Inc. announced that they will report first half, 2025 results on Aug 29, 2025お知らせ • Aug 013SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,142,500 Price\Range: HKD 25.2055お知らせ • Jun 25+ 1 more update3SBio Inc. Declares Final Dividend for the Year Ended 31 December 2024, Payable on 15 August 20253SBio Inc. announced that At the AGM held on 25 June 2025, declared a final dividend of 25 HK cents per ordinary share for the year ended 31 December 2024. As the resolution numbered 3 for the payment of the Final Dividend was duly passed at the AGM, subject to the fulfilment of the other condition as stated in the Circular, the Company will pay the Final Dividend for the year ended 31 December 2024 to the Shareholders whose names appear on the register of members of the Company as at the close of business on 25 July 2025 (the "Record Date"), and the payment date is expected to be 15 August 2025.お知らせ • Apr 173SBio Inc. Receives Breakthrough Therapy Designation by China's National Medical Products Administration3SBio Inc. on a voluntary basis. On 17 April, 2025, the anti-VEGF/PD-1 bispecific antibody (R&D code: 707 Injection), independently developed by 3SBio, was granted a Breakthrough Therapy Designation ("BTD") by China's National Medical Products Administration (" NMPA"). The designated indication is the first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer ("NSCLC"). 707 Injection is a bispecific antibody targeting VEGF/PD-1, independently developed by 3SBio based on its proprietary CLF2 platform. It is currently undergoing multiple clinical studies in China, including a phase III clinical study for the first-line treatment ofPD-1 positive locally advanced and metastatic NSCLC already approved by the Center for Drug Evaluation ("CDE") of the NMPA. Additionally, 707 Injection is undergoing several phase II studies in China, including combination therapy with chemotherapy for the first-line treatment of advanced NSCLC, metastatic colorectal cancer, and advanced gynecological tumours. It has also received approval from the U.S. Food and Drug Administration in relation to its Investigational New Drug application. The CDE will provide policy support for drugs that have been granted BTDs, prioritize resource allocation for communication, enhance guidance, and accelerate drug development. When submitting a New Drug Application, if it is evaluated to meet the relevant conditions, the qualification for priority review and approval may be granted, expediting the market launch process. There is no assurance that the product will eventually be commercialized successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.お知らせ • Mar 253SBio Inc., Annual General Meeting, Jun 25, 20253SBio Inc., Annual General Meeting, Jun 25, 2025.お知らせ • Mar 073SBio Inc. to Report Fiscal Year 2024 Results on Mar 25, 20253SBio Inc. announced that they will report fiscal year 2024 results on Mar 25, 2025お知らせ • Aug 123SBio Inc. to Report First Half, 2024 Results on Aug 22, 20243SBio Inc. announced that they will report first half, 2024 results on Aug 22, 2024お知らせ • Apr 233Sbio Inc. Announces Management Changes3SBio Inc. announced that in accordance with the articles of association of the Company, Dr. ZHANG Dan ("Dr. Zhang"), an independent non-executive Director, will retire by rotation at the forthcoming annual general meeting (the "AGM") of the Company which is to be held on 25 June 2024. He will not seek for re-election due to his other business commitments. His retirement will take effect upon the conclusion of the AGM and, accordingly, he will cease to be a member of the remuneration committee of the Board ("Remuneration Committee") at the conclusion of the AGM. The Board further announces that Mr. NG, Joo Yeow Gerry, an independent non-executive Director, has been appointed by the Board as a member of the Remuneration Committee with effect immediately after the conclusion of the 2023 AGM to be held on 25 June 2024.お知らせ • Mar 21+ 1 more update3SBio Inc., Annual General Meeting, Jun 25, 20243SBio Inc., Annual General Meeting, Jun 25, 2024.お知らせ • Mar 063SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 20243SBio Inc. announced that they will report fiscal year 2023 results on Mar 20, 2024お知らせ • Jan 09Mandi Foam of 3SBio Inc. Approves for Market Launch3SBio Inc. announced that the application for market launch of Mandi (5% minoxidil) Foam as an over-the-counter drug for the treatment of androgenetic alopecia and alopecia areata by its subsidiary, Zhejiang Wansheng Pharmaceutical Co. Ltd., to the National Medical Products Administration (NMPA) of the PRC has been approved. Mandi Foam is the new-generation anti-hair loss and hair growth product of 3SBio group based on Minoxidil Tincture (trade name: Mandi), which is also the first domestic minoxidil foam approved for market launch. Previously, the result of such product in "a multi-centered, double-blind, randomized controlled clinical trial to assess the efficacy of Mandi Foam and ROGAINE® (5% Minoxidil Foam) on patients with androgenetic alopecia in terms of their equivalence, safety and tolerability" reached the preset statistical end point, indicating that the efficacy of Mandi Foam is equivalent to that of the controlled medicine, ROGAINE®. Minoxidil is currently a first-line topical drug for the clinical treatment of androgenetic alopecia. Mandi Foam has better transdermal speed and scalp accumulation rate, with milder scalp tolerance, rendering it a better choice for alopecia users.お知らせ • Aug 123SBio Inc. to Report First Half, 2023 Results on Aug 24, 20233SBio Inc. announced that they will report first half, 2023 results on Aug 24, 2023お知らせ • Jul 293Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer3SBio Inc. announced that with effect from 3 July 2023, Mr. HE Xiang ("Mr. He") has been appointed as the new chief financial officer of the Company. Mr. He will be responsible for investment and finance activities, as well as investor relations management of the Group. The biographical details of Mr. He are as follows: Mr. He graduated from the Guanghua School of Management of Peking University with a master degree in Finance. He has served Citigroup and J.P. Morgan investment banking in Beijing, Shanghai, New York and Hong Kong, and has 15 years of experience in investments, financings, and capital markets. He is a registered sponsor principal with the Securities and Futures Commission of Hong Kong. During his tenure in J.P. Morgan, he held different roles including Head of Corporated Finance and Head of Financial Institutions for China, and gained extensive experiences in equity private placements, initial public offerings, follow-on offerings and mergers and acquisitions for various corporates across pharmaceutical, healthcare as well as other sectors.お知らせ • Jul 063SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market3SBio Inc. announced that the new drug application of narfuraphine hydrochloride orally disintegrating tablets submitted to the National Medical Products Administration of China (NMPA) being approved for launch in the market. This is a voluntary announcement made by the Company. There is no assurance that the Company will eventually successfully launch and/or commercialize the product. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. 3SBio Inc. announced that The new drug application of narfurphine hydrochloride orally disintegrated tablets (Li Mei Zhi®?, trade name in Japan; " remitsuchiODDING 2.5ug") submitted To the National Medical Products Administration ofChina (NMPA) has been approved (Guoyaozhunzi No. HJ20230091) for the improvement of pruritus in hemodialysis patients (only in cases where the efficacy of existing treatments is not satisfactory). This is the first and only selective k (kappa)-opioid receptor agonist approved by the NMPA to treat hemodialysis patients with refractory pruritus. In addition, the clinical trial application for this product to improve pruritus in patients with chronic liver disease (only in cases where the effectiveness of existing treatments is not satisfactory) was approved in May this year (Notice No.: 2023LP00912). Hemodialysis patients are often accompanied by various complications such as anemia, hypertension, abnormal calcium and phosphorus metabolism, hyperthyroidism, and pruritus. Currently, there is still no recognized effective treatment for pruritus in most of the patients, which causes great mental and physical pain to the patients and significantly reduces their quality of life.お知らせ • May 23+ 3 more updates3SBio Inc., Annual General Meeting, Jun 20, 20233SBio Inc., Annual General Meeting, Jun 20, 2023, at 10:00 China Standard Time. Location: No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone Shenyang China Agenda: To receive and adopt the audited financial statements of the Company for the year ended 31 December 2022 and the reports of the directors and auditors thereon; to declare and pay a final dividend of HKD 10 cents per ordinary share for the year ended 31 December 2022 out of the Company's share premium account to the shareholders of the Company whose name appear on the register of members of the Company as at the close of business on Monday, 3 July 2023; to re-appoint Ernst & Young as auditors of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix their remuneration for the year ending 31 December 2023; and to consider other matters.お知らせ • Jan 043SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director3SBio Inc. provided supplemental information on the resignation of Mr. Tang Ke. Mr. Tang tendered his resignation as a non-executive Director as he needs to devote more time to his personal commitments and there are no other matters in respect of his resignation that need to be brought to the attention of the Shareholders or the Stock Exchange.株主還元TRSB.FUS BiotechsUS 市場7D0%-1.8%-0.3%1Yn/a32.7%24.1%株主還元を見る業界別リターン: TRSB.FがUS Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: TRSB.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is TRSB.F's price volatile compared to industry and market?TRSB.F volatilityTRSB.F Average Weekly Movementn/aBiotechs Industry Average Movement10.9%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.2%安定した株価: TRSB.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のTRSB.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19936,109Jing Louwww.3sbio.com投資持株会社である3SBio Inc.は、中国本土および海外でバイオ医薬品の開発、製造、販売を行っている。同社は、化学療法誘発性血小板減少症および免疫性血小板減少症を治療する遺伝子組換えヒトトロンボポエチン製剤TPIAO、HER2陽性転移性乳がん治療用の抗HER2モノクローナル抗体Cipterbin、プレフィルド水性注射液TNFを提供している。また、受容体融合型腫瘍壊死因子阻害剤「YISAIPU」、OTC外用脱毛症治療薬「マンディミノキシジルチンキ」、エリスロポエチン注射剤「EPIAO」「SEPO」、注射用低分子ヘパリンカルシウム「SPARIN」を提供している。さらに、MN709ミノキシジルフォームとナルフラフィン塩酸塩錠剤も提供している。さらに、貿易、プロジェクト管理およびコンサルティング、技術、スポーツ、金融、投資顧問、医療機器の製造、農業サービスも提供している。同社は東レなどの企業と提携契約を結んでいる。3SBio社は1993年に設立され、中華人民共和国の瀋陽に本社を置いている。もっと見る3SBio Inc. 基礎のまとめ3SBio の収益と売上を時価総額と比較するとどうか。TRSB.F 基礎統計学時価総額US$6.38b収益（TTM）US$1.25b売上高(TTM)US$2.60b5.1xPER（株価収益率2.5xP/SレシオTRSB.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計TRSB.F 損益計算書（TTM）収益CN¥17.70b売上原価CN¥1.35b売上総利益CN¥16.35bその他の費用CN¥7.87b収益CN¥8.48b直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）3.39グロス・マージン92.38%純利益率47.93%有利子負債／自己資本比率8.4%TRSB.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.2%現在の配当利回り6%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/18 14:54終値2026/05/08 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋3SBio Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。35 アナリスト機関Bo YuChina International Capital Corporation LimitedZhuhong ChenChina Merchants Securities (HK) Co., LtdShitong HanCitic Securities Co., Ltd.32 その他のアナリストを表示
お知らせ • Apr 023SBio Inc. Resolves to Declare Final Dividend for the Year Ended 31 December 2025, Payable on or Around 4 August 2026The Board of 3SBio Inc. resolved to declare a final dividend of 25 HK cents per share for the year ended 31 December 2025 (2024: 25 HK cents) to those shareholders whose names appeared on the register of members of the Company on 27 July 2026, which will be paid out of the Company's share premium account. Subject to the approval of shareholders of the Company at the forthcoming annual general meeting ("AGM"), the final dividend will be paid in cash on or around 4 August 2026.
お知らせ • Mar 313SBio Inc., Annual General Meeting, Jun 25, 20263SBio Inc., Annual General Meeting, Jun 25, 2026.
お知らせ • Mar 173SBio Inc. to Report Fiscal Year 2025 Results on Mar 30, 20263SBio Inc. announced that they will report fiscal year 2025 results on Mar 30, 2026
お知らせ • Dec 103SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 033SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 193SBio Inc. to Report First Half, 2025 Results on Aug 29, 20253SBio Inc. announced that they will report first half, 2025 results on Aug 29, 2025
お知らせ • Apr 023SBio Inc. Resolves to Declare Final Dividend for the Year Ended 31 December 2025, Payable on or Around 4 August 2026The Board of 3SBio Inc. resolved to declare a final dividend of 25 HK cents per share for the year ended 31 December 2025 (2024: 25 HK cents) to those shareholders whose names appeared on the register of members of the Company on 27 July 2026, which will be paid out of the Company's share premium account. Subject to the approval of shareholders of the Company at the forthcoming annual general meeting ("AGM"), the final dividend will be paid in cash on or around 4 August 2026.
お知らせ • Mar 313SBio Inc., Annual General Meeting, Jun 25, 20263SBio Inc., Annual General Meeting, Jun 25, 2026.
お知らせ • Mar 173SBio Inc. to Report Fiscal Year 2025 Results on Mar 30, 20263SBio Inc. announced that they will report fiscal year 2025 results on Mar 30, 2026
お知らせ • Dec 103SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 033SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 193SBio Inc. to Report First Half, 2025 Results on Aug 29, 20253SBio Inc. announced that they will report first half, 2025 results on Aug 29, 2025
お知らせ • Aug 013SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,142,500 Price\Range: HKD 25.2055
お知らせ • Jun 25+ 1 more update3SBio Inc. Declares Final Dividend for the Year Ended 31 December 2024, Payable on 15 August 20253SBio Inc. announced that At the AGM held on 25 June 2025, declared a final dividend of 25 HK cents per ordinary share for the year ended 31 December 2024. As the resolution numbered 3 for the payment of the Final Dividend was duly passed at the AGM, subject to the fulfilment of the other condition as stated in the Circular, the Company will pay the Final Dividend for the year ended 31 December 2024 to the Shareholders whose names appear on the register of members of the Company as at the close of business on 25 July 2025 (the "Record Date"), and the payment date is expected to be 15 August 2025.
お知らせ • Apr 173SBio Inc. Receives Breakthrough Therapy Designation by China's National Medical Products Administration3SBio Inc. on a voluntary basis. On 17 April, 2025, the anti-VEGF/PD-1 bispecific antibody (R&D code: 707 Injection), independently developed by 3SBio, was granted a Breakthrough Therapy Designation ("BTD") by China's National Medical Products Administration (" NMPA"). The designated indication is the first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer ("NSCLC"). 707 Injection is a bispecific antibody targeting VEGF/PD-1, independently developed by 3SBio based on its proprietary CLF2 platform. It is currently undergoing multiple clinical studies in China, including a phase III clinical study for the first-line treatment ofPD-1 positive locally advanced and metastatic NSCLC already approved by the Center for Drug Evaluation ("CDE") of the NMPA. Additionally, 707 Injection is undergoing several phase II studies in China, including combination therapy with chemotherapy for the first-line treatment of advanced NSCLC, metastatic colorectal cancer, and advanced gynecological tumours. It has also received approval from the U.S. Food and Drug Administration in relation to its Investigational New Drug application. The CDE will provide policy support for drugs that have been granted BTDs, prioritize resource allocation for communication, enhance guidance, and accelerate drug development. When submitting a New Drug Application, if it is evaluated to meet the relevant conditions, the qualification for priority review and approval may be granted, expediting the market launch process. There is no assurance that the product will eventually be commercialized successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.
お知らせ • Mar 253SBio Inc., Annual General Meeting, Jun 25, 20253SBio Inc., Annual General Meeting, Jun 25, 2025.
お知らせ • Mar 073SBio Inc. to Report Fiscal Year 2024 Results on Mar 25, 20253SBio Inc. announced that they will report fiscal year 2024 results on Mar 25, 2025
お知らせ • Aug 123SBio Inc. to Report First Half, 2024 Results on Aug 22, 20243SBio Inc. announced that they will report first half, 2024 results on Aug 22, 2024
お知らせ • Apr 233Sbio Inc. Announces Management Changes3SBio Inc. announced that in accordance with the articles of association of the Company, Dr. ZHANG Dan ("Dr. Zhang"), an independent non-executive Director, will retire by rotation at the forthcoming annual general meeting (the "AGM") of the Company which is to be held on 25 June 2024. He will not seek for re-election due to his other business commitments. His retirement will take effect upon the conclusion of the AGM and, accordingly, he will cease to be a member of the remuneration committee of the Board ("Remuneration Committee") at the conclusion of the AGM. The Board further announces that Mr. NG, Joo Yeow Gerry, an independent non-executive Director, has been appointed by the Board as a member of the Remuneration Committee with effect immediately after the conclusion of the 2023 AGM to be held on 25 June 2024.
お知らせ • Mar 21+ 1 more update3SBio Inc., Annual General Meeting, Jun 25, 20243SBio Inc., Annual General Meeting, Jun 25, 2024.
お知らせ • Mar 063SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 20243SBio Inc. announced that they will report fiscal year 2023 results on Mar 20, 2024
お知らせ • Jan 09Mandi Foam of 3SBio Inc. Approves for Market Launch3SBio Inc. announced that the application for market launch of Mandi (5% minoxidil) Foam as an over-the-counter drug for the treatment of androgenetic alopecia and alopecia areata by its subsidiary, Zhejiang Wansheng Pharmaceutical Co. Ltd., to the National Medical Products Administration (NMPA) of the PRC has been approved. Mandi Foam is the new-generation anti-hair loss and hair growth product of 3SBio group based on Minoxidil Tincture (trade name: Mandi), which is also the first domestic minoxidil foam approved for market launch. Previously, the result of such product in "a multi-centered, double-blind, randomized controlled clinical trial to assess the efficacy of Mandi Foam and ROGAINE® (5% Minoxidil Foam) on patients with androgenetic alopecia in terms of their equivalence, safety and tolerability" reached the preset statistical end point, indicating that the efficacy of Mandi Foam is equivalent to that of the controlled medicine, ROGAINE®. Minoxidil is currently a first-line topical drug for the clinical treatment of androgenetic alopecia. Mandi Foam has better transdermal speed and scalp accumulation rate, with milder scalp tolerance, rendering it a better choice for alopecia users.
お知らせ • Aug 123SBio Inc. to Report First Half, 2023 Results on Aug 24, 20233SBio Inc. announced that they will report first half, 2023 results on Aug 24, 2023
お知らせ • Jul 293Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer3SBio Inc. announced that with effect from 3 July 2023, Mr. HE Xiang ("Mr. He") has been appointed as the new chief financial officer of the Company. Mr. He will be responsible for investment and finance activities, as well as investor relations management of the Group. The biographical details of Mr. He are as follows: Mr. He graduated from the Guanghua School of Management of Peking University with a master degree in Finance. He has served Citigroup and J.P. Morgan investment banking in Beijing, Shanghai, New York and Hong Kong, and has 15 years of experience in investments, financings, and capital markets. He is a registered sponsor principal with the Securities and Futures Commission of Hong Kong. During his tenure in J.P. Morgan, he held different roles including Head of Corporated Finance and Head of Financial Institutions for China, and gained extensive experiences in equity private placements, initial public offerings, follow-on offerings and mergers and acquisitions for various corporates across pharmaceutical, healthcare as well as other sectors.
お知らせ • Jul 063SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market3SBio Inc. announced that the new drug application of narfuraphine hydrochloride orally disintegrating tablets submitted to the National Medical Products Administration of China (NMPA) being approved for launch in the market. This is a voluntary announcement made by the Company. There is no assurance that the Company will eventually successfully launch and/or commercialize the product. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. 3SBio Inc. announced that The new drug application of narfurphine hydrochloride orally disintegrated tablets (Li Mei Zhi®?, trade name in Japan; " remitsuchiODDING 2.5ug") submitted To the National Medical Products Administration ofChina (NMPA) has been approved (Guoyaozhunzi No. HJ20230091) for the improvement of pruritus in hemodialysis patients (only in cases where the efficacy of existing treatments is not satisfactory). This is the first and only selective k (kappa)-opioid receptor agonist approved by the NMPA to treat hemodialysis patients with refractory pruritus. In addition, the clinical trial application for this product to improve pruritus in patients with chronic liver disease (only in cases where the effectiveness of existing treatments is not satisfactory) was approved in May this year (Notice No.: 2023LP00912). Hemodialysis patients are often accompanied by various complications such as anemia, hypertension, abnormal calcium and phosphorus metabolism, hyperthyroidism, and pruritus. Currently, there is still no recognized effective treatment for pruritus in most of the patients, which causes great mental and physical pain to the patients and significantly reduces their quality of life.
お知らせ • May 23+ 3 more updates3SBio Inc., Annual General Meeting, Jun 20, 20233SBio Inc., Annual General Meeting, Jun 20, 2023, at 10:00 China Standard Time. Location: No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone Shenyang China Agenda: To receive and adopt the audited financial statements of the Company for the year ended 31 December 2022 and the reports of the directors and auditors thereon; to declare and pay a final dividend of HKD 10 cents per ordinary share for the year ended 31 December 2022 out of the Company's share premium account to the shareholders of the Company whose name appear on the register of members of the Company as at the close of business on Monday, 3 July 2023; to re-appoint Ernst & Young as auditors of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix their remuneration for the year ending 31 December 2023; and to consider other matters.
お知らせ • Jan 043SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director3SBio Inc. provided supplemental information on the resignation of Mr. Tang Ke. Mr. Tang tendered his resignation as a non-executive Director as he needs to devote more time to his personal commitments and there are no other matters in respect of his resignation that need to be brought to the attention of the Shareholders or the Stock Exchange.
